早期宫颈癌术前近距离放疗:SFRO近距离放疗组的多中心研究
法国五家综合癌症中心回顾性分析2001至2019年间451例因不良预后因素接受术前近距离放疗的早期宫颈癌患者,完全组织学缓解率69.6%,五年无病生存率88%、局部无复发生存率98%、总生存率92%,严重不良反应1.1%至2%。
要点
- 术前近距离放疗后4至8周手术,完全组织学缓解率达69.6%。
- 五年无病生存率88%、局部无复发生存率98%、总生存率92%。
- 严重不良反应范围为1.1%至2%,腺癌、肿瘤≥2 cm及残留肿瘤为无病生存和无远处转移生存的预后因素。
核心结论
- 术前近距离放疗在该具有不良组织预后因素的患者队列中显示出优异的肿瘤学结局,生存率良好且并发症率低,支持该策略用于早期宫颈癌的管理。
研究设计与样本
- 法国五家综合癌症中心代表SFRO近距离放疗组开展的回顾性分析,纳入2001年至2019年间因不良预后因素(肿瘤大小>2 cm、存在淋巴血管浸润、腺癌)接受术前近距离放疗的早期宫颈癌患者,放疗后4至8周行手术。
主要发现
- 共识别451例患者,平均肿瘤大小为24.7 mm,腺癌占43.5%,淋巴血管间隙浸润(LVSI)存在于15.7%,完全组织学缓解率为69.6%。
- 平均随访75.4个月,五年无病生存率、局部无复发生存率和总生存率分别为88%[95%CI(84-91)]、98%[95%CI(96-99)]和92%[95%CI(87-95)]。
- 末次随访时8.2%的患者已死亡,其中31例(6.8%)死于宫颈癌。
- 严重不良反应范围为1.1%至2%。
- 多因素分析中,腺癌组织学类型、肿瘤大小≥2 cm和存在残留肿瘤是无病生存和无远处转移生存的预后因素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report the results of a multicenter cohort of preoperative brachytherapy (PBT) for treatment of early-stage cervical cancer (ESCC). METHODS: A retrospective analysis was conducted among five French comprehensive cancer centers on behalf of the SFRO Brachytherapy Group to examine the outcome of patients with ESCC who received PBT between 2001 and 2019 because of adverse prognostic factors (tumor size >2 cm, presence of lymphovascular invasion, adenocarcinoma).Brachytherapy was followed 4-8 weeks later by surgery. Local relapse free, distant metastasis-free survival, disease-free, and overall survival and adverse effects were examined. Uni- and multivariate analyses were conducted looking for oncological prognostic factors. RESULTS: A total of 451 patients were identified, with a mean tumor size of 24.7 mm. Adenocarcinoma accounted for 43.5% of cases, and lympho-vascular space invasion (LVSI) was present in 15.7%. A complete histological response was observed in 69.6%. With a mean follow-up of 75.4 months, DFS, LRFS, and OS rates at five years were 88% [95% CI (84-91), 98% [95% CI (96-99), and 92% [95% CI (87-95)], respectively. At the last follow-up, 8.2% of patients had died, including 31 (6.8%) from cervical cancer. Severe side effects range from 1.1% to 2%. At multivariate analysis, adenocarcinoma histological type, tumor size ≥2 cm, and the presence of residual tumors were prognosticators for DFS and DMFS. CONCLUSION: PBT shows excellent oncological outcomes in this cohort of patients with adverse histoprognostic factors. Favorable survival rates and low complications rates were observed, supporting this strategy in the management of ESCC.
引用
- Ka K, Cordoba A, Cagetti LV, et al. Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group. Gynecol Oncol. 2024. PMID: 38941964. doi:10.1016/j.ygyno.2024.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。